STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #576 by analyst upside · 2026-09-16
INO
Inovio Pharmaceuticals, Inc.
Healthcare · Market Cap $120M · P/E 0x
ANALYST PRICE TARGET
+173.0%
implied upside to consensus target
Current Price $1.16
Consensus Target $3.17
Bull Target $4.0
Bear Target $2.5
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
1
Hold
1
Sell
0
52-Week Low $0.56
52-Week High $2.72
YTD Return -31.4%
FUNDAMENTALS
Market Cap $120M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.01
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.56
52-Week High $2.72
Current Price $1.16
Bear Target $2.5
Bull Target $4.0
● Now $1.16 ● Target $3.17
TRADING DATA
Avg Volume 3.7M
YTD Return -31.4%
Analyst Count 3
Consensus Buy
Upside to Target +173.0%
Last Updated 2026-09-16

ANALYST SUMMARY

Inovio Pharmaceuticals, Inc. (INO) is currently trading at $1.16 with a Wall Street consensus price target of $3.17, implying potential upside of 173.0% over the next 12 months. 3 analysts currently cover INO, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $4.0, while the most cautious has a target of $2.5.

INO operates in the Healthcare sector with a market capitalisation of $120M. The stock is down 31.4% year-to-date and is currently trading near the lower end of its 52-week range of $0.56 – $2.72.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for INO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Jefferies ↑ Upgrade
Hold → Buy 2026-08-13 50% win rate (6 calls)
Piper Sandler reit
Overweight → Overweight 2026-08-03 14% win rate (7 calls)
HC Wainwright & Co. - Reiterated
Neutral → Neutral 2026-06-01 31% win rate (48 calls)
Piper Sandler reit
Overweight → Overweight 2025-11-14 14% win rate (7 calls)
HC Wainwright & Co. reit
Neutral → Neutral 2025-08-14 31% win rate (48 calls)
Piper Sandler ● Initiated
Overweight 2025-07-09 14% win rate (7 calls)
RBC Capital reit
Sector Perform → Sector Perform 2025-05-14 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2025-05-14 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
29
out of 100
Coverage depth
11/30
Consensus clarity
4/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →